At close: December 11 at 3:00:00 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 1 | 3 | 3 |
| Avg. Estimate | 0.08 | 0.07 | 0.37 | 0.34 |
| Low Estimate | 0.07 | 0.07 | 0.32 | 0.3 |
| High Estimate | 0.08 | 0.07 | 0.43 | 0.38 |
| Year Ago EPS | 0.02 | 0.1 | 0.19 | 0.37 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 8 | 12 | 12 |
| Avg. Estimate | 287.79M | 285.86M | 1.13B | 1.19B |
| Low Estimate | 284M | 272.52M | 1.13B | 1.15B |
| High Estimate | 291.8M | 293M | 1.14B | 1.22B |
| Year Ago Sales | 278.23M | 275.81M | 1.05B | 1.13B |
| Sales Growth (year/est) | 3.44% | 3.65% | 7.23% | 5.45% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.05 | 0.06 | 0.05 | 0.06 |
| EPS Actual | 0.02 | 0.1 | 0.09 | 0.05 |
| Difference | -0.03 | 0.04 | 0.04 | -0.02 |
| Surprise % | -55.65% | 67.36% | 87.84% | -27.88% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.08 | 0.07 | 0.37 | 0.34 |
| 7 Days Ago | 0.06 | 0.06 | 0.36 | 0.31 |
| 30 Days Ago | 0.06 | 0.06 | 0.34 | 0.35 |
| 60 Days Ago | 0.06 | 0.06 | 0.34 | 0.35 |
| 90 Days Ago | 0.07 | 0.06 | 0.35 | 0.35 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | 1 | 1 |
| Down Last 30 Days | -- | -- | 1 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| GTBIF | 267.65% | -30.00% | 93.23% | -8.04% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Maintains | Wedbush: Outperform to Outperform | 5/10/2024 |
| Maintains | Needham: Buy to Buy | 5/9/2024 |
| Maintains | Needham: Buy to Buy | 2/29/2024 |
| Initiated | Zuanic & Associates: Overweight | 11/7/2023 |
| Reiterates | Needham: Buy | 5/4/2023 |
| Reiterates | Benchmark: Buy | 3/1/2023 |
Related Tickers
TCNNF Trulieve Cannabis Corp.
4.8300
-7.12%
CURLF Curaleaf Holdings, Inc.
1.6900
-0.59%
CRLBF Cresco Labs Inc.
1.0000
-3.85%
VRNOF Verano Holdings Corp.
1.2700
+0.79%
AYRWF Ayr Wellness Inc.
0.4400
-18.52%
CBSTF The Cannabist Company Holdings Inc.
0.0780
-15.77%
JUSHF Jushi Holdings Inc.
0.2920
+2.28%
OGI Organigram Holdings Inc.
1.5200
-1.30%
CRON Cronos Group Inc.
1.9500
-2.99%
TSNDF TerrAscend Corp.
0.6830
-6.44%